Changing the Concept of ACRP-CP Exam Preparation 2025
Getting ACRP-CP Certification Made Easy! Get professional help from our ACRP-CP Dumps PDF
NEW QUESTION # 65
An investigator in a multicenter trial reports multiple occurrences of an SAE to the sponsor. Who is responsible for reporting the SAEs to the remaining sites' IRB/IECs?
- A. Regulatory authority
- B. Study sponsor
- C. Original reporting investigator
- D. Investigator at each site
Answer: B
Explanation:
The study sponsor is responsible for disseminating information about SAEs to all participating sites. This ensures consistent and timely communication of safety concerns, allowing each site to take appropriate actions in line with local regulations and IRB/IEC requirements.
The answer aligns with ICH E6(R2) GCP guidelines which mandate the sponsor to communicatesafety information to all investigators and sites involved in a multicenter trial.
"The sponsor must inform all investigators of safety information that could affect the conduct of the trial or the safety of subjects." Objectives:
* Maintain consistent safety reporting across all trial sites.
* Ensure regulatory compliance in multicenter trials.
NEW QUESTION # 66
Which of the following reports should be retained in participant charts?
- A. IRB/IEC progress reports
- B. Lab reports
- C. Safety reports
- D. DSMB/IDMC reports
Answer: B
Explanation:
Lab reports contain individual participant data relevant to their health status and the study's outcomes. These reports are essential for verifying subject safety and evaluating the effects of the investigational product (IP).
Therefore, they must be retained in the participant's medical records.
According to GCP guidelines, participant charts must include laboratory data as part of the essential documents to ensure accurate and complete clinical records.
"Lab reports must be maintained as part of the participant's chart for safety monitoring and data verification." Objectives:
* Maintain comprehensive medical records for each participant.
* Ensure availability of clinical data for audit and review.
NEW QUESTION # 67
Per protocol, participants are scheduled to receive IP, which is calculated based on the participant's current weight. Unknown to the pharmacist, a participant recently lost 15 pounds and was overdosed as a result. What is the FIRST action the CRC must take to ensure the participant's safety?
- A. Notify the PI.
- B. Call the participant to return for an unscheduled visit.
- C. Notify the sponsor.
- D. Report a protocol deviation to the IRB/IEC.
Answer: A
Explanation:
The CRC's first responsibility is to immediately inform the Principal Investigator (PI), who is responsible for the participant's medical care. The PI will assess the situation, determine the potential risk, and initiate appropriate clinical actions to ensure the participant's safety. This may include medical evaluation or adjusting the dosing regimen.
According to GCP guidelines, any issue that may affect participant safety should be promptly communicated to the PI to ensure appropriate medical management.
"The investigator must be informed immediately of any events that could compromise participant safety, allowing for prompt clinical decision-making." Objectives:
* Ensure rapid response to dosing errors.
* Maintain participant safety as a priority.
NEW QUESTION # 68
The site submitted all start-up documents for a study to the sponsor and the IRB/IEC. The site also has subjects identified for screening. What should happen FIRST?
- A. Ship/receive IP
- B. Schedule a site initiation visit
- C. Obtain IRB/IEC approval
- D. Verify subject eligibility
Answer: C
Explanation:
Before proceeding with any trial-related activities, including subject screening, the site must first obtain IRB
/IEC approval. This approval ensures that the study has been reviewed for ethical considerations, risk assessment, and adherence to regulatory requirements. Without IRB/IEC approval, initiating the study would violate ethical guidelines and regulatory standards.
GCP guidelines mandate that no clinical trial procedures, including screening, commence without prior IRB
/IEC approval.
"IRB/IEC approval must be obtained before initiating any study-related activities, including screening and subject recruitment." Objectives:
* Ensure ethical compliance before study initiation.
* Protect participant rights and safety.
NEW QUESTION # 69
Which of the following would the sponsor need to do FIRST to set up an effective clinical trial quality management system (QMS)?
- A. Identify critical processes and data during protocol development.
- B. Perform a periodic review to see if the quality methods are effective and relevant.
- C. Train the research coordinator on the required study assessments schedule.
- D. Determine the quality tolerance limits for data transcription errors.
Answer: A
Explanation:
The first step in establishing a robust quality management system (QMS) is to identify critical processes and data during protocol development. This step ensures that quality objectives are clear and that monitoring and quality control efforts are focused on the most significant aspects of the study. By understanding critical data points and processes early, the sponsor can design a more effective QMS to manage risks.
GCP guidelines emphasize identifying critical data and processes at the earliest stages to develop a risk-based quality management approach.
"Identification of critical data and processes at the protocol development stage is essential for designing an effective quality management system." Objectives:
* Establish quality oversight from the start.
* Implement a risk-based monitoring approach.
NEW QUESTION # 70
SAEs must be reported immediately by the site to the:
- A. Regulatory agency.
- B. Sponsor.
- C. DSMB/IDMC.
- D. IRB/IEC.
Answer: B
Explanation:
Serious Adverse Events (SAEs) must be reported immediately to the sponsor. The sponsor then assesses the severity, causality, and potential impact on the study and decides whether further reporting to regulatory authorities and IRB/IEC is required. Immediate reporting ensures that appropriate actions are taken to safeguard participant safety.
GCP guidelines specify that the site must notify the sponsor immediately about any SAE to ensure timely safety assessment and reporting.
"Sites must report all serious adverse events immediately to the sponsor, who will then determine the appropriate regulatory and ethical reporting requirements." Objectives:
* Ensure rapid reporting of serious adverse events.
* Maintain safety monitoring during the trial.
NEW QUESTION # 71
Who is responsible for defining, establishing, and allocating all trial-related duties and functions prior to initiating a trial?
- A. Sponsor
- B. Investigator
- C. IRB/IEC
- D. CRO
Answer: A
Explanation:
The sponsor is responsible for defining, establishing, and allocating all trial-related duties and functions before the trial begins. This includes outlining roles and responsibilities in collaboration with investigators, CROs, and other stakeholders. Proper delegation ensures the trial is conducted according to protocol and regulatory requirements.
This answer is verified based on GCP guidelines, which clearly state that sponsors are responsible for the organization and management of trial-related tasks.
"The sponsor is responsible for allocating duties and functions related to the conduct of the trial, ensuring compliance with regulatory and ethical standards." Objectives:
* Clarify the sponsor's role in clinical trial management
* Define responsibilities in trial planning
NEW QUESTION # 72
Which of the following activities is the MOST efficient way of overseeing a CRO's management during a clinical trial?
- A. Co-monitoring of CRO site visits
- B. Risk-based audits of CRO activities as delegated
- C. Pre-qualification assessment of CRO
- D. Central monitoring of data fields by sponsor
Answer: B
Explanation:
Risk-based audits of CRO activities as delegated are considered the most efficient way of overseeing a CRO's management. This approach focuses on evaluating the critical risks that might impact data integrity and participant safety. It allows sponsors to allocate resources to areas with the highest potential for error or deviation, rather than performing exhaustive monitoring of all activities.
The answer is verified as per guidelines on risk-based monitoring strategies, emphasizing targeted and efficient oversight of CRO functions.
"Risk-based monitoring emphasizes focusing on critical study parameters and the risks that have the potential to affect data quality and subject safety." Objectives:
* Efficient management of outsourced clinical trial tasks.
* Ensuring data integrity through targeted audits.
NEW QUESTION # 73
A study drug will be shipped, stored, and mixed at the hospital pharmacy and will be transferred to the study site for infusion. Which document describes how the transfer will occur?
- A. Data & Safety Monitoring Plan
- B. Clinical Monitoring Plan
- C. Standard Operating Procedure
- D. Investigator's Brochure
Answer: C
Explanation:
The Standard Operating Procedure (SOP) outlines the process for shipping, storing, mixing, and transferring the investigational product (IP) between locations. SOPs ensure that all steps are consistently followed and documented, maintaining the integrity and quality of the IP throughout the handling process. This is critical for maintaining compliance with Good Clinical Practice (GCP) and ensuring patient safety.
GCP guidelines specify that SOPs should cover the handling, transfer, and storage of investigational products to ensure quality control.
"SOPs provide detailed guidance on the handling and transfer of investigational products to ensure consistency and compliance." Objectives:
* Maintain the integrity of IP during transport and handling.
* Ensure compliance through standardized procedures.
NEW QUESTION # 74
Who should vote during the IRB/IEC review and discussion process?
- A. All members who were involved in the review and discussion and non-member experts
- B. All members who were involved in the review and discussion
- C. All IRB/IEC members and non-member experts
- D. All IRB/IEC members
Answer: B
Explanation:
During the IRB/IEC review process, only members who actively participated in the review and discussion are eligible to vote. This ensures that votes are cast by those who are adequately informed about the study and can make an educated decision. Non-member experts may participate in discussions but do not have voting rights.
GCP guidelines state that voting rights in IRB/IEC meetings are limited to members who have thoroughly reviewed and discussed the study, maintaining unbiased and informed decision-making.
"Only IRB/IEC members who were involved in the review and discussion should participate in the voting process." Objectives:
* Ensure informed voting in ethical review processes.
* Maintain integrity and objectivity in IRB/IEC decisions.
NEW QUESTION # 75
Prior to initiation of a clinical trial, review by an IRB/IEC is required for which of the following documents?
- A. Protocol, IB, and information about payments and compensation available to subjects
- B. IB, site coordinator CVs, and information about payments and compensation available to subjects
- C. Protocol, informed consent, and clinical trial agreement
- D. Protocol, site coordinator CVs, and clinical trial agreement
Answer: A
Explanation:
Before a clinical trial can begin, the IRB/IEC must review the protocol, Investigator's Brochure (IB), and any information related to payments and compensation. This review ensures that the study is ethically sound, scientifically valid, and that participants are informed about any financial considerations.
GCP guidelines specify that essential documents, including the protocol, IB, and compensation details, must be reviewed by the IRB/IEC to maintain ethical oversight.
"The IRB/IEC must evaluate the protocol, IB, and any financial disclosures to ensure ethical compliance and participant protection." Objectives:
* Guarantee ethical oversight in clinical trial conduct.
* Protect participants through informed consent and transparency.
NEW QUESTION # 76
A deferred consent can take place in which of the following situations?
- A. Only when the PI approves such a consent process immediately prior to patient enrollment, regardless of the situation being classed as emergency.
- B. In an emergency situation only, when this process is described in the protocol and has received permission from the ethics committee.
- C. In an emergency situation only, even when this process is not described in the protocol, but the sponsor approves the consent process.
- D. Only when the PI approves such a consent process, regardless of the emergency situation described in the protocol.
Answer: B
Explanation:
Deferred consent is permissible in emergency situations where immediate intervention is necessary and obtaining prior consent is not feasible. However, this practice must be explicitly described in the protocol and approved by the ethics committee. This ensures that the rights of patients are protected even in urgent circumstances.
GCP guidelines emphasize that deferred consent is only allowed when pre-approved by the ethics committee as part of the protocol for emergency interventions.
"In emergencies, deferred consent is permitted only if outlined in the protocol and approved by the ethics committee, ensuring compliance with ethical standards." Objectives:
* Protect patient rights in emergency research.
* Ensure ethical approval for deferred consent.
NEW QUESTION # 77
A quality assurance audit of the EDC system SOP revealed a deficiency. Which of the following is the MOST likely reason?
- A. The number of users with access was not defined.
- B. The frequency of data backup was not defined.
- C. The list of comparable technology solutions was not included.
- D. The number of unique eCRF templates was not specified.
Answer: B
Explanation:
The frequency of data backup is a critical element of an Electronic Data Capture (EDC) system's Standard Operating Procedure (SOP). Ensuring regular and systematic data backup is essential for protecting trial data against loss or corruption. Failure to specify backup frequency indicates a gap in data security management.
GCP guidelines stress that data protection, including regular backups, is essential to maintaining data integrity in clinical trials.
"EDC system SOPs must include clear guidelines on data backup frequency to safeguard the integrity and availability of study data." Objectives:
* Ensure data security through regular backups.
* Maintain data integrity in clinical research.
NEW QUESTION # 78
The inclusion and exclusion criteria are in place so all subjects are:
- A. Medically appropriate and protected from ethical vulnerability.
- B. Healthy and willing to complete the clinical trial.
- C. Ethically vulnerable and patients with the disease under study.
- D. Patients with the disease under study and will not have any adverse events.
Answer: A
Explanation:
Inclusion and exclusion criteria are designed to ensure that participants are medically appropriate for the study and are not ethically vulnerable. This reduces risks to subjects and ensures that the collected data accurately reflects the target population.
The answer follows GCP principles that emphasize participant safety and data validity through well-defined inclusion/exclusion criteria.
"Inclusion and exclusion criteria are crucial for ensuring the safety of participants and the scientific validity of study results." Objectives:
* Ensuring participant safety.
* Maintaining ethical standards in clinical research.
NEW QUESTION # 79
A site has reported multiple temperature excursions for an IP, primarily because the air conditioning (A/C) gets shut off after business hours. A separate A/C unit cannot be installed in the room where the IP is kept.
What would be the MOST effective long-term mitigation strategy?
- A. Return all IP and request the CRO/Sponsor to directly ship IP to participants.
- B. Continue reporting temperature excursions per the pharmacy manual guidelines.
- C. Invest in a room temperature controlled IP cabinet and transfer IP to this unit.
- D. Install an air cooler requiring regular water refills to maintain the room temperature.
Answer: C
Explanation:
Investing in a temperature-controlled IP cabinet is the most effective and sustainable solution for maintaining IP stability. This cabinet can consistently regulate temperature without relying on external A/C systems, thereby minimizing the risk of excursions and ensuring compliance with storage requirements.
GCP guidelines state that IP must be stored under controlled conditions as specified by the protocol and product labeling.
"Temperature-controlled storage units should be used when site environmental conditions are not reliable to maintain IP stability." Objectives:
* Ensure IP stability and compliance.
* Mitigate temperature excursion risks effectively.
NEW QUESTION # 80
In addition to members who collectively have the qualifications and experience to review and evaluate the science, medical aspects, and ethics of the proposed trial, it is recommended that the IRB/IEC should include:
- A. A total of five members.
- B. One member who is independent of the institution/trial site.
- C. One member whose primary area of interest is in the same scientific area.
- D. One member of the site's QA group.
Answer: B
Explanation:
The IRB/IEC should include at least one member who is not affiliated with the institution or trial site to ensure impartiality and objectivity in the review process. This helps maintain ethical oversight without internal biases influencing the decisions.
This answer is based on ICH E6(R2) GCP guidelines, which mandate the inclusion of non-affiliatedmembers to uphold the integrity of the ethical review process.
"The IRB/IEC should include at least one member who is not associated with the institution to provide an unbiased perspective." Objectives:
* Maintain impartiality in ethical review.
* Ensure diverse representation within the IRB/IEC.
NEW QUESTION # 81
Who is responsible for securing agreement from all involved parties to ensure direct access of all trial-related source documents?
- A. Sponsor
- B. Investigator
- C. CRC
- D. CRO
Answer: A
Explanation:
The sponsor is responsible for ensuring that agreements are in place with all involved parties (including investigators and institutions) to grant direct access to trial-related source documents. This is crucial for monitoring, auditing, and inspection purposes, ensuring transparency and compliance with regulatory requirements.
According to GCP guidelines, the sponsor must establish agreements to secure direct access to trial data for verification and compliance checks.
"The sponsor should ensure that agreements are in place to permit direct access to source data and documents for monitoring and inspection." Objectives:
* Maintain compliance with regulatory requirements.
* Facilitate data verification and quality assurance.
NEW QUESTION # 82
......
ACRP-CP Exam Crack Test Engine Dumps Training With 127 Questions: https://www.actual4dump.com/ACRP/ACRP-CP-actualtests-dumps.html
Obtain the ACRP-CP PDF Dumps Get 100% Outcomes Exam Questions For You To Pass: https://drive.google.com/open?id=1qUuOKvCWBqhkkhEEe6w0tIRvUrqggqaC